Shaperon   Report issue

For profit Phase 3
Founded: Gangnam Korea, Republic of (2013)

Organization Overview

First Clinical Trial
2018
NCT03492398
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shaperon | Shaperon Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Taurodeoxycholate (Nusepin) (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Pneumonia (Phase 2)

Sepsis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1